Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs

Entrada Therapeutics doses first participant in Exon 44 skipping program; provides updates to other exon-skipping programs

Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of several exon skipping programs.  We are pleased to share that they have dosed the first participant in the ELEVATE-44-201 clinical trial for individuals with Duchenne amenable to skipping Exon 44.  They expect to report clinical data from the first cohort during the first half of 2026.  This study is currently enrolling ambulatory particip…